NAS:BDSI (USA) Also trade in: Germany

BioDelivery Sciences International Inc

$ 4.39 -0.04 (-0.9%)
Volume: 1,001,731 Avg Vol (1m): 1,083,298
Market Cap $: 383.71 Mil Enterprise Value $: 394.67 Mil
P/E (TTM): 0.00 P/B: 11.36
Earnings Power Value -21.62
Net Current Asset Value -0.2
Tangible Book -0.15
Projected FCF -6.55
Median P/S Value 5.41
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.79
Cash-To-Debt ranked lower than
92.67% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
BDSI: 0.79
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.05, Med: 2.89, Max: 10000
Current: 0.79
0.05
10000
Equity-to-Asset 0.25
Equity-to-Asset ranked lower than
92.53% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
BDSI: 0.25
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -2.52, Med: 0.31, Max: 0.87
Current: 0.25
-2.52
0.87
Debt-to-Equity 1.90
Debt-to-Equity ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
BDSI: 1.9
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -23.62, Med: 0.25, Max: 35.66
Current: 1.9
-23.62
35.66
Debt-to-EBITDA -4.73
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
BDSI: -4.73
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -4.73, Med: -0.41, Max: 11.89
Current: -4.73
-4.73
11.89
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -1.09
DISTRESS
GREY
SAFE
Beneish M-Score -2.16
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -45.52%
WACC -0.17%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -26.19
Operating Margin ranked higher than
51.14% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
BDSI: -26.19
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -827.09, Med: -86.21, Max: 63.88
Current: -26.19
-827.09
63.88
Net Margin % -42.09
Net Margin ranked lower than
51.26% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
BDSI: -42.09
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -714.83, Med: -108.67, Max: 52.61
Current: -42.09
-714.83
52.61
ROE % -146.34
ROE ranked lower than
93.23% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
BDSI: -146.34
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -957, Med: -218.4, Max: 6.13
Current: -146.34
-957
6.13
ROA % -25.56
ROA ranked lower than
68.91% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
BDSI: -25.56
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -100.92, Med: -37.45, Max: 124.67
Current: -25.56
-100.92
124.67
ROC (Joel Greenblatt) % -407.55
ROC (Joel Greenblatt) ranked lower than
66.41% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
BDSI: -407.55
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1925.31, Med: -716.18, Max: 2073.85
Current: -407.55
-1925.31
2073.85
3-Year Total Revenue Growth Rate 4.90
3-Year Revenue Growth Rate ranked higher than
66.36% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
BDSI: -1.5
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: -64.8, Med: 4.95, Max: 418.2
Current: -1.5
-64.8
418.2
3-Year Total EBITDA Growth Rate 19.40
3-Year EBITDA Growth Rate ranked higher than
69.20% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
BDSI: 24.3
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -16.45, Max: 24.3
Current: 24.3
0
24.3
3-Year EPS w/o NRI Growth Rate -0.50
3-Year EPS w/o NRI Growth Rate ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
BDSI: -0.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -49.65, Max: 30.1
Current: -0.5
0
30.1

» BDSI's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:BDSI

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare XPAR:VLA NAS:XBIT NAS:CNST XKRX:217730 XKRX:268600 TSE:4588 XKRX:174900 NAS:UBX TSE:7774 XKRX:214450 XKRX:001630 NAS:INSY NAS:GERN LSE:HZD ASX:SPL SZSE:002898 NAS:KIN SHSE:603229 NAS:MRUS NAS:AGEN
Traded in other countries BD5.Germany
Address 4131 ParkLake Avenue, Suite 225, Raleigh, NC, USA, 27612
BioDelivery Sciences International is a biotechnology company that specializes in pain management and addiction medicine. The company's products and candidates are based on BioErodible MucoAdhesive, a proprietary B drug delivery technology. BEMA is a small, erodible polymer film for application to the buccal mucosa, which is used in approved products and candidates such as ONSOLIS (fentanyl buccal soluble film) for treating cancer pain; BUNAVAIL (buprenorphine and naloxone buccal film) to treat opioid dependence; and product candidate BELBUCA (formerly referred to as BEMA Buprenorphine), which aims to treat chronic pain.

Ratios

Current vs industry vs history
PB Ratio 11.36
PB Ratio ranked lower than
99.38% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
BDSI: 11.36
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.32, Med: 7.55, Max: 104.35
Current: 11.36
2.32
104.35
PS Ratio 4.61
PS Ratio ranked higher than
77.41% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
BDSI: 4.61
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.89, Med: 5.67, Max: 1156.67
Current: 4.61
0.89
1156.67
EV-to-EBIT -23.49
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
BDSI: -23.49
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -58.8, Med: -3.9, Max: 32.5
Current: -23.49
-58.8
32.5
EV-to-EBITDA -35.69
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
BDSI: -35.69
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -118.3, Med: -4.2, Max: 23
Current: -35.69
-118.3
23
EV-to-Revenue 6.18
EV-to-Revenue ranked higher than
73.67% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
BDSI: 6.18
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 0.4, Med: 5.2, Max: 1067
Current: 6.18
0.4
1067
Current Ratio 2.88
Current Ratio ranked lower than
83.89% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
BDSI: 2.88
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.03, Med: 1.42, Max: 6.96
Current: 2.88
0.03
6.96
Quick Ratio 2.57
Quick Ratio ranked lower than
83.80% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
BDSI: 2.57
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.03, Med: 1.23, Max: 6.96
Current: 2.57
0.03
6.96
Days Inventory 132.08
Days Inventory ranked lower than
54.47% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
BDSI: 132.08
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 67.55, Med: 96.06, Max: 132.94
Current: 132.08
67.55
132.94
Days Sales Outstanding 91.11
Days Sales Outstanding ranked lower than
52.69% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
BDSI: 91.11
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 3.49, Med: 40.79, Max: 91.11
Current: 91.11
3.49
91.11
Days Payable 59.40
Days Payable ranked higher than
78.54% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
BDSI: 59.4
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 59.4, Med: 564.49, Max: 2025.55
Current: 59.4
59.4
2025.55

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -6.20
3-Year Share Buyback Rate ranked higher than
84.95% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
BDSI: -6.2
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -38.1, Med: -16.1, Max: -1.2
Current: -6.2
-38.1
-1.2

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.81
Price-to-Median-PS-Value ranked higher than
74.48% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
BDSI: 0.81
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.16, Med: 2.05, Max: 222.67
Current: 0.81
0.16
222.67
Earnings Yield (Joel Greenblatt) % -4.27
Earnings Yield (Greenblatt) ranked lower than
80.67% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
BDSI: -4.27
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -256.7, Med: -19.8, Max: 148.9
Current: -4.27
-256.7
148.9

More Statistics

Revenue (TTM) (Mil) $ 64.13
EPS (TTM) $ -0.58
Beta -0.54
Volatility % 49.57
52-Week Range $ 2.23 - 5.37
Shares Outstanding (Mil) 87.4

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y